Company Profile

Alzheon Inc is a United States-based clinical-stage biopharmaceutical company. The company is developing medicines for patients suffering from alzheimer's disease and other neurological and psychiatric disorders. The Company is focused on brain health, memory and aging and develops treatments for alzheimer's disease and other neurodegenerative disorders.

Employees

Sector

Biotechnology & Medical Research

More about the company

Alzheon, Inc. Announces Two Peer-Reviewed Scientific Publications Describe Fluid Biomarker, Brain Preservation and Clinical Benefits Following 2 Years of Treatment in Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease	Jun. 25	CI
Alzheon, Inc Announces Appointment of Gino Santini to Board of Directors	Jun. 12	CI
Alzheon, Inc. announced that it has received $100 million in funding	Jun. 11	CI
Alzheon, Inc. Announces First Patient Dosed in Long-Term Extension of APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate and Launches 52-Week Extension of Phase 2 Biomarker Trial in Patients with Early Alzheimer's Disease	Apr. 30	CI
Alzheon, Inc. announced a financing transaction	Feb. 26	CI
Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer	Dec. 05	CI
Alzheon, Inc. to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at 16th Annual Clinical Trials in Alzheimer's Disease Conference	23-10-17	CI
Alzheon To Present Pivotal Program of Oral ALZ-801/Valiltramiprosate at Singularity Conference, Goldman Sachs Alzheimer?s Disease Day, and BIO Investor Forum	23-09-26	CI
Alzheon Reports Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 in Patients with Early Alzheimer's Disease	23-09-13	CI
Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet	23-07-11	CI
Alzheon, Inc. to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study At American Academy of Neurology Conference in Boston	23-04-18	CI
Alzheon, IncAnnounces Early Completion of Enrollment of APOLLOE4 Phase 3 Clinical Trial Evaluating Oral ALZ-801 (Valiltramiprosate) in APOE4/4 Homozygotes with Early Alzheimer’s Disease	22-12-06	CI
Alzheon, Inc. announced that it expects to receive $50.004201 million in funding	22-11-29	CI

Director	Title	Age	Since
Martin Tolar FOU	Founder	59	13-05-31
Kenneth A. Mace DFI	Director of Finance/CFO	52	15-08-31
Adem Albayrak COO	Chief Operating Officer	-	21-09-12

Manager	Title	Age	Since
Martin Tolar FOU	Founder	59	13-05-31
Neil Flanzraich CHM	Chairman	81	18-08-05
Jordan Heller BRD	Director/Board Member	62	20-01-07

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
LONZA GROUP AG	+2.25%	+3.47%	+13.39%	-28.56%	47.27B
IQVIA HOLDINGS INC.	+0.13%	-1.80%	+12.09%	-7.32%	43.52B
ALNYLAM PHARMACEUTICALS, INC.	+1.35%	+7.49%	+37.40%	+41.12%	34.06B
CELLTRION, INC.	-0.20%	+2.09%	+32.25%	-21.27%	30.33B
MODERNA, INC.	-2.01%	-6.32%	-39.47%	-84.04%	26.25B
ICON PUBLIC LIMITED COMPANY	+0.10%	-0.83%	+14.60%	+13.07%	24.84B
UNITED THERAPEUTICS CORPORATION	-0.58%	-1.88%	+54.50%	+62.67%	15.09B
BIO-TECHNE CORPORATION	+2.01%	+4.45%	+0.85%	-41.42%	11.85B
MEDPACE HOLDINGS, INC.	+1.95%	+4.74%	+25.58%	+94.22%	10.88B
Average	+0.56%	+1.21%	+16.80%	+3.16%	27.12B
Weighted average by Cap.	+0.57%	+1.14%	+15.77%	-5.38%

Alzheon, Inc. Stock

Equities

ALZH

US00168L1017

Biotechnology & Medical Research

Latest news: Alzheon, Inc.

Managers and Directors: Alzheon, Inc.

Other Biotechnology & Medical Research

Company Profile